Bevacizumab Biosimilars Market Size, Share, Growth, Opportunity and Forecast to 2032
Posted by ramacharitbrc on November 14th, 2023
The Bevacizumab Biosimilars Global Market Report 2023, provides comprehensive information on the bevacizumab biosimilars market across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032
Learn More On The Bevacizumab Biosimilars Market’s Growth:
https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report
The global bevacizumab biosimilars market size is expected to grow from .31 billion in 2022 to .43 billion in 2023 at a compound annual growth rate (CAGR) of 9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global bevacizumab biosimilars market size is expected to reach .93 billion in 2027 at a CAGR of 7.9%.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=10848&type=smp
Product innovation has emerged as a key trend gaining popularity in the bevacizumab biosimilars market. Major market players are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in May 2022, Viatris, a US-based pharmaceutical company, and Biocon Biologics, a US-based pharmaceutical company, launched a biosimilar called Abevmy® (bevacizumab), which is a biosimilar similar to Roche's Avastin® (bevacizumab). Abevmy has received approval from Health Canada for use across four oncology indications. The product offers efficacy, safety, and quality similar to the reference biologic, as it is a synthesized humanized monoclonal antibody (MA) that binds to and neutralizes the biologic action of human vascular endothelial growth factor (VEGF).
The bevacizumab biosimilars market is segmented:
1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer
North America was the largest region in the bevacizumab biosimilars market in 2022.
Top 5 Major Key Players Are:
Hetero Drugs Ltd
Amgen Inc
Biocon Ltd
Mylan Inc
BioXpress Therapeutics SA
Table Of Contents
1. Executive Summary
2. Bevacizumab Biosimilars Market Characteristics
3. Bevacizumab Biosimilars Market Trends And Strategies
4. Bevacizumab Biosimilars Market - Macro Economic Scenario
5. Bevacizumab Biosimilars Market Size And Growth
.......
26. Africa Bevacizumab Biosimilars Market
27. Bevacizumab Biosimilars Market Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions In The Bevacizumab Biosimilars Market
29. Bevacizumab Biosimilars Market Future Outlook and Potential Analysis
30. Appendix
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.
